PIK3CA mutation in Chinese patients with lung squamous cell carcinoma

被引:5
作者
Yu, Jinglin [1 ]
Bai, Hua [1 ]
Wang, Zhijie [1 ]
Wei, Zhigang [1 ]
Ding, Xiaosheng [1 ]
Duan, Jianchun [1 ]
Yang, Lu [1 ]
Wu, Meina [1 ]
Wang, Yuyan [1 ]
Wang, Jie [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
关键词
Lung squamous cell carcinoma (LSCC); PIK3CA mutation; EGFR mutation; KRAS mutation; GROWTH-FACTOR RECEPTOR; HIGH-FREQUENCY; HUMAN CANCERS; GENE; CHEMOTHERAPY; GEFITINIB; ERLOTINIB; SURVIVAL; RAS;
D O I
10.3978/j.issn.1000-9604.2013.08.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate PIK3CA mutation in Chinese patients with lung squamous cell carcinoma (LSCC) and explore their relationship with clinicopathological profiles. Methods: Tumor samples from 123 cases of LSCC were included in this study. PIK3CA mutations in exon 9 and 20 were screened by pyrosequencing and confirmed by clone sequencing or amplification refractory mutation system (ARMS). Denaturing performance liquid chromatography (DHPLC) was employed for evaluation of EGFR mutation in exon 19, 21 and KRAS mutation. Results: PIK3CA mutations were found in 3 (2.4%) patients. The mutation type included E545K, E452Q and H1047R. Of these three patients, one coupled with EGFR mutation, and the other two coupled with PIK3CA amplification. All the three patients shared the same clinicopathologic characteristics: male, less than 60 years old, had smoke history, stage III and carried wild-type KRAS. Conclusions: The frequency of PIK3CA mutation is low in Chinese patients with LSCC. The mutational status of PIK3CA is not mutually exclusive to EGFR mutation.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 31 条
[1]   The PIK3CA gene is mutated with high frequency in human breast cancers [J].
Bachman, KE ;
Argani, P ;
Samuels, Y ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Konishi, H ;
Karakas, B ;
Blair, BG ;
Lin, C ;
Peters, BA ;
Velculescu, VE ;
Park, BH .
CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775
[2]   Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].
Bai, Hua ;
Mao, Li ;
Wang, Hang Shu ;
Zhao, Jun ;
Yang, Lu ;
An, Tong Tong ;
Wang, Xin ;
Duan, Chun Jian ;
Wu, Na Mei ;
Guo, Zhi Qing ;
Liu, Yi Xu ;
Liu, Hong Ning ;
Wang, Ye Yu ;
Wang, Jie .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659
[3]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[4]   Whole genome sequencing for lung cancer [J].
Daniels, Marissa ;
Goh, Felicia ;
Wright, Casey M. ;
Sriram, Krishna B. ;
Relan, Vandana ;
Clarke, Belinda E. ;
Duhig, Edwina E. ;
Bowman, Rayleen V. ;
Yang, Ian A. ;
Fong, Kwun M. .
JOURNAL OF THORACIC DISEASE, 2012, 4 (02) :155-163
[5]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[6]  
Edge SB, 2010, AJCC CANC STAGING MA, P237
[7]  
Endoh H, 2006, J THORAC ONCOL, V1, P629
[8]   Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes [J].
Fisher, GH ;
Wellen, SL ;
Klimstra, D ;
Lenczowski, JM ;
Tichelaar, JW ;
Lizak, MJ ;
Whitsett, JA ;
Koretsky, A ;
Varmus, HE .
GENES & DEVELOPMENT, 2001, 15 (24) :3249-3262
[9]   Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].
Fukuoka, Masahiro ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Sunpaweravong, Patrapim ;
Leong, Swan-Swan ;
Sriuranpong, Virote ;
Chao, Tsu-Yi ;
Nakagawa, Kazuhiko ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Duffield, Emma L. ;
Rukazenkov, Yuri ;
Speake, Georgina ;
Jiang, Haiyi ;
Armour, Alison A. ;
To, Ka-Fai ;
Yang, James Chih-Hsin ;
Mok, Tony S. K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874
[10]   EGFR testing in lung cancer is ready for prime time [J].
Hirsch, Fred R. ;
Bunn, Paul A., Jr. .
LANCET ONCOLOGY, 2009, 10 (05) :432-433